Literature DB >> 10147048

The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

M Johannesson1.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 10147048     DOI： 10.2165/00019053-199202050-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

1.  Economic evaluation of drug therapy: a review of the contingent valuation method.

Authors:  M Johannesson; P O Johansson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

2.  Principles of cost-effective resource allocation in health care organizations.

Authors:  M C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  1990       Impact factor: 2.188

Review 3.  The use of QALYs in health care decision making.

Authors:  G Loomes; L McKenzie
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

Review 4.  Economic evaluation in health care: is there a role for cost-benefit analysis?

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1991-02       Impact factor: 2.980

5.  Economic evaluation of lipid lowering--a feasibility test of the contingent valuation approach.

Authors:  M Johannesson
Journal:  Health Policy       Date:  1992       Impact factor: 2.980

Review 6.  Cost-effectiveness analysis of hypertension treatment--a review of methodological issues.

Authors:  M Johannesson; B Jönsson
Journal:  Health Policy       Date:  1991-09       Impact factor: 2.980

7.  Risk reduction from low osmolality contrast media. What do patients think it is worth?

Authors:  L J Appel; E P Steinberg; N R Powe; G F Anderson; S A Dwyer; R R Faden
Journal:  Med Care       Date:  1990-04       Impact factor: 2.983

8.  Willingness to pay and accept risks to cure chronic disease.

Authors:  M S Thompson
Journal:  Am J Public Health       Date:  1986-04       Impact factor: 9.308

9.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

10.  Cost-benefit analysis of non-pharmacological treatment of hypertension.

Authors:  M Johannesson; H Aberg; L Agréus; L Borgquist; B Jönsson
Journal:  J Intern Med       Date:  1991-10       Impact factor: 8.989
View more
  7 in total

Review 1.  Economic evaluation of drugs and its potential uses in policy making.

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

2.  The Australian Guidelines for subsidisation of pharmaceuticals.

Authors:  D A Henry
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

3.  Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

Authors:  K Clemens; R Townsend; F Luscombe; J Mauskopf; J Osterhaus; J Bobula
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

4.  The emerging government requirement for economic evaluation of pharmaceuticals.

Authors:  M Drummond
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 5.  Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosis.

Authors:  K L Goa; H Lamb
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

6.  Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.

Authors:  Thomas Faunce; Evan Doran; David Henry; Peter Drahos; Andrew Searles; Brita Pekarsky; Warwick Neville
Journal:  Global Health       Date:  2005-10-06       Impact factor: 4.185

7.  Predicting preference-based utility values using partial proportional odds models.

Authors:  Roberta Ara; Ben Kearns; Ben A vanHout; John E Brazier
Journal:  BMC Res Notes       Date:  2014-07-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.